



12<sup>th</sup> February 2024

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.  
**BSE Scrip Code 524518**

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai- 400051.  
**NSE Scrip Code: KREBSBIO**

**Sub: Outcome of Board Meeting under Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.**

**Dear Sir/Madam,**

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Unaudited Financial Results of the Company along with limited review report issued by the Statutory Auditors of the Company for 3<sup>rd</sup> Quarter and 9 month ended 31<sup>st</sup> December 2023 which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

The Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 1:20 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully  
For **Krebs Biochemicals and Industries Limited**

**Keyur Doshi**  
Company Secretary  
ACS 32107

Encl.: a/a

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110API991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31,2023**

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		(Un Audited)	(Un Audited)	(Un Audited)	(Un Audited)	(Un Audited)	(Audited)
1	Revenue from Operations	1,297.72	1,489.01	909.07	3,844.86	4,067.39	5213.44
2	Other Income	2.94	17.42	2.29	24.11	42.69	62.01
3	<b>Total Income from operations (1+2)</b>	<b>1,300.66</b>	<b>1,506.43</b>	<b>911.36</b>	<b>3,868.97</b>	<b>4,110.08</b>	<b>5,275.46</b>
4	Expenses						
	a) Cost of Material Consumed	103.09	62.79	310.97	362.51	1,505.68	1,536.24
	b) Purchase of Stock in Trade	-	-	1.58	-	440.22	444.41
	c) Changes in Inventories of Finished goods, Work-In-Progress	24.65	142.59	(149.63)	7.14	306.89	587.10
	d) Employee Benefits Expenses	444.47	408.89	391.01	1,259.74	1,133.51	1,584.41
	e) Finance Costs	118.62	113.41	89.82	341.76	194.47	297.32
	f) Depreciation and Amortisation Expense	173.05	171.08	169.28	509.45	507.84	655.85
	g) Other Expenses	934.51	964.79	653.76	2,776.51	1,796.70	2,639.32
	<b>Total Expenses (4)</b>	<b>1,798.39</b>	<b>1,863.56</b>	<b>1,466.79</b>	<b>5,257.11</b>	<b>5,885.30</b>	<b>7,744.65</b>
5	<b>Profit / (Loss) before exceptional items and tax (3±4)</b>	<b>(497.74)</b>	<b>(357.13)</b>	<b>(555.43)</b>	<b>(1,388.15)</b>	<b>(1,775.22)</b>	<b>(2,469.19)</b>
6	Exceptional Items:	-	-	-	-	-	-
7	<b>Profit / (Loss) before Tax (5 ± 6)</b>	<b>(497.74)</b>	<b>(357.13)</b>	<b>(555.43)</b>	<b>(1,388.15)</b>	<b>(1,775.22)</b>	<b>(2,469.19)</b>
8	Tax Expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	<b>Profit / (Loss) for the period (7 ± 8)</b>	<b>(497.74)</b>	<b>(357.13)</b>	<b>(555.43)</b>	<b>(1,388.15)</b>	<b>(1,775.22)</b>	<b>(2,469.19)</b>
10	Other Comprehensive Income (OCI)						
i	Items that will not be reclassified to profit or Loss	-	-	-	-	-	32.28
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-	-	-	-	-
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>32.28</b>
11	<b>Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)</b>	<b>(497.74)</b>	<b>(357.13)</b>	<b>(555.43)</b>	<b>(1,388.15)</b>	<b>(1,775.22)</b>	<b>(2,436.91)</b>
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	(13,207.37)
14	<b>Earning Per Share (of Rs.10/- each) (not Annualised)</b>						
	a) Basic	(2.31)	(1.66)	(2.58)	(6.44)	(8.23)	(11.30)
	b) Diluted	(2.31)	(1.66)	(2.58)	(6.44)	(8.23)	(11.30)
15	<b>Net Worth (including Retained Earnings)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(9,946.23)</b>


See accompanying notes to the Financial results

1 The above results have been reviewed by the Audit Committee at its meeting held on 12th February, 2024 and approved by the Board of Directors of the Company at its meeting held on 12th February, 2024. The results are subjected to limited review by statutory auditors.


2 The Company is operating in one segment only hence no segment results have been disclosed.

3 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.


Place: Mumbai  
Date: 12.02.2024



*Handwritten signature*




*Handwritten signature*  
Jitendra Shah  
Managing Director  
DIN : 09377846




**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
KREBS BIOCHEMICALS AND INDUSTRIES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of KREBS BIOCHEMICALS ANDI INDUSTRIES LIMITED ("the Company"), for the quarter ended December 31, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.



For **BHAVANI & CO**  
Chartered Accountants  
(Firm's Registration No. 012139S)

  
**CA. S. KAVITHA PADMINI**  
Partner  
(Membership No. 229966)  
UDIN: 24229966BKBLV17356

Place : Mumbai  
Date : 12-02-2024